Tumor-associated macrophages in glioblastoma multiforme - A suitable target for somatostatin receptor-based imaging and therapy?

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Lapa, Constantin ^a   Linsenmann, Thomas ^a   Lückerath, Katharina ^a   Samnick, Samuel ^a   Herrmann, Ken ^a   Stoffer, Carolin ^b   Ernestus, Ralf Ingo ^a   Buck, Andreas K ^a   Löhr, Mario ^a   Monoranu, Camelia Maria ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD68 ANTIGEN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2A; TRACER; UNCLASSIFIED DRUG; [1,4,7,10 TETRAAZACYCLODODECANE NN',N',N' TETRAACETIC ACID] DEXTRO PHENYLALANINE, TYROSINE OCTREOTATE GA 68; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; DOTATATE GALLIUM GA-68; LEUKOCYTE ANTIGEN; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; MOLECULAR IMAGING; NEUROPIL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; BRAIN NEOPLASMS; CHEMISTRY; DIAGNOSTIC IMAGING; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES;

EID: 84926372398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122269     Document Type: Article

References (46)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology. 2012; Suppl 5: v1-v49
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466 doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
3. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011; 70: 9-21 doi: 10.1002/ana.22425 PMID: 21786296
4. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. PMID: 15758009
5. Holland EC. Glioblastoma multiforme: the terminator. PNAS. 2000; 97: 6242-6244. PMID: 10841526
6. Huysentruyt LC, Mukherjee P, Banerjee D, Shelton LM, Seyfried TN. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int J Cancer. 2008; 123: 73-84 doi: 10.1002/ijc.23492 PMID: 18398829
7. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg. 1979; 50: 305-311 PMID: 422981
8. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE. Astrocytic regulation of human monocytic/microglial activation. J Immunol. 2008; 181: 5425-5432 PMID: 18832699
9. Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia. 2011; 59: 472-485 doi: 10.1002/glia.21117 PMID: 21264953
10. Markovic DS, Glass R, Synowitz M, Rooijen Nv, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005; 64: 754-762 PMID: 16141784
11. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion - an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene. 2008; 27: 918-930 PMID: 17684491
12. Wagner S, Czub S, Greif M, Vince GH, Süss N, Kerkau S, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Intl J Cancer. 1999; 82: 12-16
13. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003; 3: 489-501. PMID: 12835669
14. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves EGFR and CSF-1R signaling. Mol Med. 2012; 18: 519-527 doi: 10.2119/molmed.2011.00217 PMID: 22294205
15. Davidson SE, West CM, Hunter RD. Lack of association between in vitro clonogenic growth of human cervical carcinoma and tumour stage, differentiation, patient age, host cell infiltration or patient survival. Int J Cancer. 1992; 50: 10-14 PMID: 1728599
16. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005; 14: 425-431 PMID: 16012726
17. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000; 60: 5857-5861 PMID: 11059783
18. Flamm J, Benesch A. Tumor-associated mononuclear cell infiltrate and recurrence rate in the superficial urothelial carcinoma of the urinary bladder. Urol Int. 1986; 41: 187-19 PMID: 3750579
19. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999; 5: 1107-1113 PMID: 10353745
20. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20: 157-198. PMID: 10433861
21. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995; 16: 427-42 PMID: 8521788
22. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007; 34: 982-993 PMID: 17225119
23. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27: 273-282 PMID: 10774879
24. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2001; 52 Suppl 2: 42S-55S. doi: 10.2967/jnumed.110.085753 PMID: 22144555
25. Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides. 200; 21: 1941-1964 PMID: 11150654
26. Dalm VA, van Hagen PM, van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DH, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003; 285: E344-E353 PMID: 12684217
27. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007; 81: 845-855 PMID: 17148691
28. Feindt J, Becker I, Blomer U, Hugo HH, Mehdorn HM, Krisch B, et al. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem. 1995; 65: 1997-2005 PMID: 7595483
29. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76: 620-27 PMID: 9610716
30. Mawrin C, Schulz S, Pauli SU, Treuheit T, Diete S, et al. (2004) Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas. J Neuropathol Exp Neurol. 63: 13-19 PMID: 14748557
31. Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol. 2002; 14: 458-471 PMID: 12047721
32. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res. 1987; 47: 5758-5764. PMID: 2889527
33. ] Heute D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC. J Nucl Med. 2010; 51: 397-400. doi: 10.2967/jnumed.109.072819 PMID: 20150267
34. Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012; 7: 99. doi: 10.1186/1748-717X-7-99 PMID: 22720902
35. Hänscheid H, Sweeney RA, Flentje M, Buck AK, Löhr M, Samnick S, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012; 39:1284-1288. doi: 10.1007/s00259-012-2124-x PMID: 22526964
36. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007; 114: 97-109 PMID: 17618441
37. Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Sem Nucl Med. 2011; 41:314-21 doi: 10.1053/j.semnuclmed.2011.02.001 PMID: 21624565
38. Bourdier T, Greguric I, Roselt P, Jackson T, Faragalla J, Katsifis A. Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FX(FN) module. Nucl Med Biol. 2011; 38: 645-651. doi: 10.1016/j.nucmedbio.2011.01.001 PMID: 21718939
39. Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin. 2011; 50: 167-173 doi: 10.3413/nuk-2011041 PMID: 21789338
40. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, et al. Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas. J Nucl Med. 2010; 51: 1532-1538 doi: 10.2967/jnumed.110.078592 PMID: 20847166
41. Leenstra S, Das PK, Troost D, de Boer OJ, Bosch DA. Human malignant astrocytes express macrophage phenotype. J Neuroimmunol. 1995; 56:17-25. PMID: 7822478
42. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009; 29: 3269-3279. PMID: 19661345
43. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003; 73: 209-212. PMID: 12554797
44. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3: 23-35. PMID: 12511873
45. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008; 216: 15-24. doi: 10.1002/path.2370 PMID: 18553315
46. Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012; 103: 2165-2172 doi: 10.1111/cas.12015 PMID: 22957741